

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 5 : C07D 471/04, A61K 31/44 // (C07D 471/04, 235:00, 221:00)</p>		A1	<p>(11) International Publication Number: WO 93/09119 (43) International Publication Date: 13 May 1993 (13.05.93)</p>		
<p>(21) International Application Number: PCT/US92/09018 (22) International Filing Date: 22 October 1992 (22.10.92)</p>		<p>(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).</p>			
<p>(30) Priority data: 788,565 6 November 1991 (06.11.91) US</p>		<p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>			
<p>(71) Applicant: MINNESOTA MINING AND MANUFACTURING COMPANY [US/US]; 3M Center, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).</p>					
<p>(72) Inventors: GERSTER, John, F. ; WEEKS, Charles, E. ; Post Office Box 33427, Saint Paul, MN 55133-3427 (US).</p>					
<p>(74) Agents: REEDICH, Douglas, E. et al.; Office of Intellectual Property Counsel, Post Office Box 33427, Saint Paul, MN 55133-3427 (US).</p>					
<p>(54) Title: ANTIVIRAL 2-ETHYL-1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES</p>					
<p></p>					
<p></p>					
<p></p>					
<p>(57) Abstract</p>					
<p>2-Ethyl 1H-imidazo[4,5-c]quinolin-4-amines of formula (I), active as immunomodulators and antiviral agents. Also, intermediates of formulae (II, III) in the preparation of such compounds, pharmaceutical compositions, and pharmacological methods of use.</p>					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BC	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MC	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

ANTIVIRAL 2-ETHYL-1H-IMIDAZO(4,5-C)QUINOLIN-4-AMINES

BACKGROUND OF THE INVENTION

5 Field of the Invention

This invention relates to 1H-imidazo[4,5-c]-quinoline compounds. In other aspects, this invention relates to 1H-imidazo[4,5-c]quinolin-4-amines, intermediates for the preparation of such compounds, pharmaceutical compositions containing such compounds, and pharmacological methods of using such compounds. This invention also relates to methods of inducing biosynthesis of tumor necrosis factor.

15 Description of the Related Art

The first reliable report of the 1H-imidazo[4,5-c]quinoline ring system, Backman et al., J. Org. Chem. 15, 1278-1284 (1950), describes the synthesis of 1-(6-methoxy-8-quinolinyl)-2-methyl-1H-imidazo[4,5-c]-quinoline for possible use as an antimalarial agent. Subsequently, syntheses of various substituted 1H-imidazo[4,5-c]quinolines have been reported. For example, Jain et al., J. Med. Chem. 11, pp. 87-92 (1968), has synthesized the compound 1-[2-(4-piperidyl)ethyl]-1H-imidazo[4,5-c]quinoline as a possible anticonvulsant and cardiovascular agent. Also, Baranov et al., Chem. Abs. 85, 94362 (1976), has reported several 2-oxoimidazo[4,5-c]quinolines, and Berenyi et al., J. Heterocyclic Chem. 18, 1537-1540 (1981), has reported certain 2-oxoimidazo[4,5-c]-quinolines.

Certain antiviral 1H-imidazo[4,5-c]quinolin-4-amines are described in U.S. Pat. No. 4,689,338 (Gerster). These compounds are substituted on the 1-position by alkyl, hydroxyalkyl, acyloxyalkyl, benzyl, phenylethyl or substituted phenylethyl, and at the 2-position with hydrogen, alkyl, benzyl, or

- 2 -

substituted benzyl, phenylethyl or phenyl. Furthermore, these compounds are known to induce interferon biosynthesis. Other antiviral 1H-imidazo[4,5-c]quinolin-4-amines, substituted on the 5 1-position by alkenyl substituents, are described in U.S. Pat. No. 4,929,624 (Gerster).

U.S. Pat. No. 4,698,348 (Gerster) discloses 1H-imidazo[4,5-c]quinolines that are active as bronchodilators, such as 4-substituted 1H-imidazo- 10 [4,5-c]quinolines wherein the 4-substituent is, inter alia, hydrogen, chloro, alkylamino, or dialkylamino, and the 2-substituent is, inter alia, hydroxyalkyl, aminoalkyl, or alkanamidoalkyl. Said patent also discloses 3-amino and 3-nitro quinoline intermediates 15 substituted at the 4-position by hydroxyalkylamino or cyclohexylmethylamino, and 1H-imidazo[4,5-c]quinoline N-oxide intermediates substituted at the 2-position with, inter alia, hydroxyalkyl, aminoalkyl, or alkanamidoalkyl.

20 Tumor necrosis factor (TNF) is an endogenic glycoprotein that has the capability to selectively destroy tumor cells. For this reason there is considerable interest in TNF as a cancer therapeutic agent.


25 Biosynthesis of tumor necrosis factor has been induced by immunomodulators such as interleukin-2, and by catabolic enzymes such as those disclosed in European Patent Application 0,421,023A (Ransberger et al.).

30

DETAILED DESCRIPTION OF THE INVENTION
This invention provides compounds of Formula I:

- 3 -

5




I

wherein R₁ is 2-methylpropyl or 2-hydroxy-2-methylpropyl.

This invention also provides intermediate compounds of Formula II:

15




II

20 wherein R₁ is defined above.

This invention also provides intermediate compounds of Formula III:

25



III

30 wherein R₁ is as defined above.

The compounds of the invention can be prepared as set forth in the Examples below.

A compound of Formula I can be used in the form of a free base or it can be used in the form of a 35 pharmaceutically acceptable acid-addition salt such as a hydrochloride, dihydrogen sulfate, trihydrogen

- 4 -

phosphate, hydrogen nitrate, methanesulfonate or a salt of another pharmaceutically acceptable acid. A pharmaceutically acceptable acid-addition salt of a compound of Formula I can be prepared by reaction of 5 the compound with an equimolar amount of a relatively strong acid, preferably an inorganic acid such as hydrochloric, sulfuric, or phosphoric acid, or an organic acid such as methanesulfonic acid, in a polar solvent. Isolation of the salt is facilitated by the 10 addition of a solvent, such as diethyl ether, in which the salt is insoluble.

The compounds of Formula I can be utilized to achieve a desired pharmacological effect by administration to a patient in an appropriately 15 formulated pharmaceutical composition. Suitable pharmaceutical compositions comprise a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula I. The amount or concentration of a compound of Formula I that 20 constitutes a therapeutically effective amount will depend of course on the particular desired pharmacological effect, on the route of administration, and on the particular formulation being used. Suitable therapeutically effective amounts can be selected by 25 those skilled in the art.

Suitable pharmaceutical compositions include those suitable for oral, parenteral (including subcutaneous, intramuscular, intraperitoneal, and intravenous), buccal, rectal, or transdermal administration, or 30 administration by inhalation.

Pharmaceutical compositions for oral administration can take the form of tablets, capsules, suspensions, solutions, or emulsions. Tablets can comprise pharmaceutically acceptable excipients such as 35 diluents, binding agents, lubricants, disintegrants, flavors, colors, and the like. Liquid preparations can be prepared by conventional means with pharmaceutically

- 5 -

acceptable excipients such as suspending agents, emulsifying agents, vehicles, preservatives, colors, sweetening agents, and the like. Compositions for oral administration can be formulated to give controlled 5 release of the active compound by use of suitable pharmaceutically acceptable polymers.

Pharmaceutical compositions for parenteral administration can take the form of solutions, suspensions, or emulsions in aqueous or oily vehicles 10 and can comprise pharmaceutically acceptable excipients such as buffering agents, tonicity adjusters, suspending agents, emulsifiers, and the like.

Pharmaceutical compositions for buccal administration can take the form of tablets or 15 lozenges. Alternatively, the active compound can be incorporated into a transmucosal delivery device. Transmucosal delivery devices can comprise a backing and a matrix containing the active compound, a buccal adhesive, and optionally a penetration enhancer.

20 Pharmaceutical compositions for rectal administration can take the form of suppositories prepared by combining the active compound with conventional suppository bases.

Pharmaceutical compositions for transdermal 25 administration can take the form of creams or lotions comprising pharmaceutically acceptable excipients such as ointment bases, oils, preservatives, emulsifiers, skin penetration enhancers, and the like.

Alternatively, the active compound can be incorporated 30 into a transdermal delivery device. The transdermal delivery device can be in the form of a bandage comprising a backing layer, a reservoir containing the active compound, optionally with other excipients, optionally a rate controlling membrane, and means for 35 securing the device to the skin. Alternatively, the transdermal delivery device can comprise a backing

- 6 -

layer with an adhesive matrix containing the active compound and optionally one or more excipients.

Pharmaceutical compositions for administration by inhalation can take the form of solutions, suspensions, 5 or powders that can be delivered by means of a pressurized aerosol container or a nebulizer.

The compounds of Formula I exhibit antiviral activity in mammals. They can therefore be used to control viral infections. For example, a compound of 10 Formula I can be used as an agent to control infections in mammals caused by Type II Herpes simplex virus. Compounds of Formula I can also be used to treat a herpes infection by oral, topical, or intraperitoneal administration.

15 The compounds of Formula I were tested and found to induce biosynthesis of interferon in human cells. The test methods and results are set forth below. These results suggest that compounds of the invention might be useful in treating other diseases such as 20 rheumatoid arthritis, warts, eczema, Hepatitis B, psoriasis, multiple sclerosis, essential thrombocythaemia, cancer such as basal cell carcinoma, and other neoplastic diseases.

The compounds of Formula I have been shown by the 25 test methods set forth below to induce biosynthesis of tumor necrosis factor (TNF) in human cells. Moreover, the compounds of Formula I induce TNF biosynthesis when administered at lower dose concentrations than structurally related compounds of the prior art. Thus 30 the compounds of Formula I have potential as cancer therapeutic agents, e.g., for local (e.g., topical, rectal, vaginal) administration or aerosol administration.

In the following Examples, the particular 35 materials and amounts thereof recited as well as other conditions and details, should not be construed to unduly limit the invention.

- 7 -

EXAMPLE 1

2-Ethyl-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline

A 16.55 g (0.077 mol) portion of N⁴-(2-methylpropyl)-3,4-quinolinediamine (U.S. Pat. No. 4,689,338 example 16) was suspended in 100 mL of propionic acid and then heated at 120°C for about 20 hours. After cooling to room temperature, the reaction mixture was poured into 300 mL of water, made basic with concentrated ammonium hydroxide, cooled in an ice bath and then extracted with diethyl ether. The volume of the ether extract was reduced under vacuum. The resulting precipitate was collected, rinsed with ether and dried to provide 11 g of crystalline solid, m.p. 72-73.5°C. Analysis: Calculated for C₁₆H₁₉N₃: %C, 75.8; %H, 7.6; %N, 16.6; Found: %C, 75.6; %H, 7.7; %N, 16.5.

EXAMPLE 2

2-Ethyl-1-(2-methylpropyl)-1H-imidazo-[4,5-c]quinoline 5N Oxide

A 9.92 mL portion of peracetic acid was added to a solution of 10.65 g (0.042 mol) of 2-ethyl-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline in 100 mL of ethyl acetate. The mixture was heated at reflux for about 2 hours and then cooled to room temperature. A precipitate was collected, rinsed with ethyl acetate and dried to provide 4 g of a yellow solid, m.p. 177-180°C. This material was used without further purification.

30

EXAMPLE 3

2-Ethyl-1-(2-methylpropyl)-1H-imidazo-[4,5-c]quinolin-4-amine

A 3.7 g (0.014 mol) portion of 2-ethyl-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline 5N oxide was suspended in 35 mL of methylene chloride, cooled in an ice bath and then combined with 45 mL of chilled

- 8 -

ammonium hydroxide. The resulting two phase mixture was stirred vigorously with cooling in an ice bath while a solution of 2.87 g (0.015 mol) of tosyl chloride in 30 mL of methylene chloride was slowly added. The reaction 5 mixture was allowed to slowly warm to room temperature with stirring. The methylene chloride was evaporated to provide an orange solid which was collected, rinsed with water and air dried. The solid was then recrystallized from methylene chloride containing a 10 trace of methanol to provide 2.7 g of a white solid, m.p. 233-234°C. Analysis: Calculated for $C_{16}H_{20}N_4$: %C, 71.6; %H, 7.5; %N, 20.9; Found: %C, 71.3; %H, 7.3; %N, 20.6.

15

EXAMPLE 4

α,α -Dimethyl-2-ethyl-1H-imidazo-[4,5-c]quinoline-1-ethanol

A mixture containing 15.4 g (0.067 mol) of 1-[(3-amino-4-quinoliny1)amino]-2-methyl-2-propanol (U.S. 20 Pat. No. 4,689,338 example 189) and 14.5 mL (0.07 mol) of triethyl orthopropionate was heated at about 165°C for about 2 hours. The resulting solid was slurried in a mixture of ethyl acetate and ether, collected and dried to provide 15.2 g of a solid. This material was 25 used without further purification.

EXAMPLE 5

2-Ethyl-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinoline 5N Oxide

30 Using the general method of Example 2, 15.2 g of α,α -dimethyl-2-ethyl-1H-imidazo[4,5-c]quinoline-1-ethanol was oxidized to provide 15.2 g of crude N oxide. A sample was dissolved in water then precipitated by the addition of sodium hydroxide. The 35 precipitate was collected and dried to provide a solid, m.p. 245-250°C. Analysis: Calculated for $C_{16}H_{19}N_3O_2 + \frac{1}{2}H_2O$:

- 9 -

%C, 65.3; %H, 6.8; %N, 14.3; Found: %C, 65.2; %H, 6.4;
%N, 14.0.

EXAMPLE 6

5 4-Amino- α,α -dimethyl-2-ethyl-1H-imidazo[4,5-c]-
quinoline-1-ethanol

Using the general method of Example 3, 14.3 g (0.05 mol) of 2-ethyl-1-(2-hydroxy-2-methylpropyl)-1H-imidazo[4,5-c]quinoline 5N oxide was aminated to 10 provide 8.2 g of crude product. This material was recrystallized from 60 mL of ethanol to provide 6.4 g of solid, m.p. 222-225°C. Analysis: Calculated for C₁₆H₂₀N₄O: %C, 67.6; %H, 7.1; %N, 19.7; Found: %C, 67.6; %H, 7.1; %N, 19.7.

15

COMPARATIVE EXAMPLE C1

4-Amino- α,α ,2-trimethyl-1H-imidazo[4,5-c]-
quinoline-1-ethanol

A mixture containing 1.5 g (0.0056 mol) of 1-[(3-amino-2-chloro-4-quinoliny)amino]-2-methyl-2-propanol (U.S. Pat. No. 4,988,815 example 13), 1.4 g (0.0085 mol) of triethyl orthoacetate and 4 mL of xylenes was heated at 135-140°C for 6 hours. The solution was evaporated to provide a beige oil comprising 4-chloro-25 α,α ,2-trimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol which was used without further purification.

The crude material was combined with 15 mL of 15% methanolic ammonia and heated in a steel bomb at about 150°C for 7 hours. The reaction mixture was partially 30 evaporated then diluted with a small amount of water. The resulting precipitate was collected, rinsed sequentially with methanol, water, then methanol and dried to provide 900 mg of crude product. The crude product was recrystallized from methanol/methylene 35 chloride to provide 500 mg of colorless crystals, m.p.

- 10 -

290-293°C. Analysis: Calculated for C₁₅H₁₈N₄O: %C, 66.6; %H, 6.7; %N, 20.7; Found: %C, 66.6; %H, 6.7; %N, 20.6.

COMPARATIVE EXAMPLE C2

5 2-Methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c]-quinolin-4-amine

This compound can be prepared by known methods. See for example U.S. Pat. No. 4,689,338 example 113.

10 COMPARATIVE EXAMPLE C3

1-(2-Methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine

This compound can be prepared by known methods. See for example U.S. Pat. No. 4,689,338 example 99 or U.S. Pat. No. 4,988,815 example 10.

15 COMPARATIVE EXAMPLE C4

4-Amino- α,α -dimethyl-1H-imidazo-[4,5-c]quinoline-1-ethanol

This compound can be prepared by known methods. See for example U.S. Pat. No. 4,689,338 example 189.

The 2-ethyl 1H-imidazo[4,5-c]quinolin-4-amines of the invention and comparative compounds were tested according to the methods set forth below:

25 TUMOR NECROSIS FACTOR (α) INDUCTION IN HUMAN CELLS

This test method is an assay for tumor necrosis factor (α) induction in human mononuclear cells in culture. Activity is based on the measurement of human tumor necrosis factor (α) secreted into culture medium. Human tumor necrosis factor (α) is measured by radioimmunoassay.

Blood Cell Preparation for Culture

35 Whole blood is collected by venipuncture into EDTA (K₃) vacutainer tubes. Peripheral blood mononuclear

- 11 -

- cells (PBM's) are prepared by LeucoPREPTM Brand Cell Separation Tubes (available from Becton Dickinson Labware, Lincoln Park, NJ) and cultured in RPMI 1640 medium (available from GIBCO, Grand Island, NY)
- 5 supplemented with 25 mM HEPES (N-2-hydroxyethyl-piperazine-N'-2-ethanesulfonic acid) and L-glutamine with 1% penicillin-streptomycin solution added) with 10% autologous serum (heat inactivated, 56°C for 30 minutes) added. 200 μ L portions of PBM's in medium are
- 10 added to 96 well (flat bottom) MicroTestTM III tissue culture plates (available from Falcon Plastics, Oxnard, CA).

Compound Preparation

- 15 Test compounds are solubilized in water, ethanol or dimethyl sulfoxide then diluted with distilled water, 0.01N sodium hydroxide or 0.01N hydrochloric acid (The choice of solvent will depend on the chemical characteristics of the compound being tested.). It is
- 20 preferred that the final concentration of ethanol or dimethylsulfoxide, if used, does not exceed 1%. Compounds are initially tested in a concentration range of about 0.5 μ g/mL to about 5 μ g/mL. Compounds which show induction at a concentration of 0.5 μ g/mL are then
- 25 tested in a concentration range of 0.01 μ g/mL to 0.5 μ g/mL.

Incubation

- The solution of test compound is added in a
- 30 predetermined volume (less than or equal to 50 μ L) to the wells containing 200 μ L of PBM's in medium. Solvent and/or medium is added to control wells (i.e., wells containing no test compound) and as needed to the test wells in order to adjust the final volume of each
- 35 well to 250 μ L. The plates are covered with plastic

- 12 -

lids, vortexed gently and then incubated for 18 hours at 37°C with a 5% carbon dioxide atmosphere.

Separation

- 5 Following incubation, the plates are covered with PARAFILM™ laboratory film and then centrifuged at 1000 rpm for 15 minutes at 4°C in a Damon IEC Model CRU-5000 centrifuge. Medium (about 200 μ L) is removed from 4 to 8 wells and pooled into 2 mL sterile freezing vials.
- 10 Samples are maintained at -70°C until analysis.

Tumor necrosis factor (α) analysis/calculation

- Tumor necrosis factor (α) is measured using an Enzyme Immuno Assay (available from Biosource International, California). Results are expressed as picograms/mL based on a standard curve conducted for each assay. Lipopolysaccharide, a known inducer of tumor necrosis factor (α), is included in each assay and is used to provide a comparison of response for each culture and assay. Lipopolysaccharide has been evaluated in this test method over a range 0.01 to 5 μ g/mL and typically gives a response of 1000 to 3000 picograms/mL.

25

RESULTS

- The compounds of the invention and comparative compounds were screened side-by-side in two separate assays. The results are shown in Tables 1 and 2. The blood used to run the assay of Table 1 was obtained 30 from a different donor than that used to run the assay of Table 2.

- 13 -

TABLE 1

TUMOR NECROSIS FACTOR (α) INDUCTION IN HUMAN CELLS

		<u>TNF (α) (picograms/mL)</u>			Solvent
	Compound	Dose	Concentration (μ g/mL)		
5	of Example	<u>0.5</u>	<u>1.0</u>	<u>5.0</u>	
	3	1109	1519	1274	DMSO
	6	950	1938	3740	DMSO
	C1	438	653	2186	DMSO
	C2	617	849	1203	DMSO
10	C3	235	302	380	water
	C4	671	295	607	water
	LPS	2580	2681	2648	water
	Control	90			

15

TABLE 2

TUMOR NECROSIS FACTOR (α) INDUCTION IN HUMAN CELLS

		<u>TNF (α) (picograms/mL)</u>				Solvent
	Compound	Dose	Concentration (μ g/mL)			
20	of Example	<u>0.01</u>	<u>0.05</u>	<u>0.1</u>	<u>0.5</u>	
	3	19	126	408	1742	DMSO
	6	26	94	262	1554	DMSO
	C1	17	48	43	613	DMSO
	C2	35	44	46	1076	DMSO
25	C3	15	51	39	53	water
	C4	25	32	37	39	water
	LPS	1620	1840	1812	1799	water
	Control	42				

30

The results in TABLES 1 and 2 show that the compounds of Examples 3 and 6 induce biosynthesis of TNF in human cells when administered at lower dose concentrations than structurally related compounds of 35 the prior art.

- 14 -

INTERFERON (α) INDUCTION IN HUMAN CELLS

An in vitro human blood cell system was used to assess interferon induction by compounds of the invention. Activity is based on the measurement of 5 interferon secreted into culture medium. Interferon is measured by bioassay.

Blood Cell Preparation for Culture

Whole blood is collected by venipuncture into EDTA 10 vacutainer tubes. Peripheral blood mononuclear cells (PBM's) are prepared by LeucoPREPTM Brand Cell Separation Tubes (available from Becton Dickinson) and cultured in RPMI 1640 medium (available from GIBCO, Grand Island, NY) supplemented with 25 mM HEPES (N-2- 15 hydroxyethylpiperazine-N'-2-ethanesulfonic acid) and L-glutamine (1% penicillin-streptomycin solution added) with 10% autologous serum (heat inactivated, 56°C for 30 minutes) added. 200 μ L portions of PBM's in medium 20 are added to 96 well (flat bottom) MicroTestTM III tissue culture plates (available Falcon Plastics).

Compound Preparation

The compounds are solubilized in water, ethanol or dimethyl sulfoxide then diluted with distilled water, 25 0.01N sodium hydroxide or 0.01N hydrochloric acid (The choice of solvent will depend on the chemical characteristics of the compound being tested.). Compounds are initially tested in a concentration range of from about 0.1 μ g/mL to about 5 μ g/mL. Compounds 30 which show induction at a concentration of 0.5 μ g/mL are then tested in a concentration range of 0.01 μ g/mL to 5.0 μ g/mL/.

Incubation

35 The solution of test compound is added in a volume (less than or equal to 50 μ L) to the wells containing

- 15 -

200 μ L of PBM's in medium. Solvent and/or medium is added to control wells (i.e., wells containing no test compound) and as needed to the test wells in order to adjust the final volume of each well to 250 μ L. The 5 plates are covered with plastic lids, vortexed gently and then incubated for 24 hours at 37°C with a 5% carbon dioxide atmosphere.

Separation

10 Following incubation, the plates are covered with PARAFILM™ laboratory film and then centrifuged at 1000 rpm for 15 minutes at 4°C in a Damon IEC Model CRU-5000 centrifuge. Medium (about 175 μ L) is removed from 4 to 8 wells and pooled into 2 mL sterile freezing vials.

15 Samples are maintained at -70°C until analysis.

Interferon Analysis/Calculation

Interferon is determined by bioassay using A549 human lung carcinoma cells challenged with 20 encephalomyocarditis. The details of the bioassay method have been described by G. L. Brennan and L. H. Kronenberg in "Automated Bioassay of Interferons in Micro-test Plates", Biotechniques, June/July; 78, 1983. Briefly stated the method is as follows: interferon 25 dilutions and A549 cells are incubated at 37°C for 12 to 24 hours. The incubated cells are infected with an inoculum of encephalomyocarditis virus. The infected cells are incubated for an additional period at 37°C before quantifying for viral cytopathic effect. The 30 viral cytopathic effect is quantified by staining followed by spectrophotometric absorbance measurements. Results are expressed as (α) reference units/mL based on the value obtained for NIH HU IF-L standard. The interferon was identified as essentially all interferon 35 (α) by testing in checkerboard neutralization assays against rabbit anti-human interferon (β) and goat anti-

- 16 -

human interferon (α) using A549 cell monolayers challenged with encephalomyocarditis virus.

RESULTS

5 Results are shown in Table 3 wherein the absence of an entry indicates that the compound was not tested at the particular dose concentration. Results designated as "<" a certain number indicate that interferon was not detectable in amounts above the 10 lower sensitivity level of the assay.

TABLE 3
INTERFERON (α) INDUCTION IN HUMAN CELLS

15	Compound of	Reference units/mL					
		Dose concentration ($\mu\text{g/mL}$)					
Example	<u>0.01</u>	<u>0.05</u>	<u>0.1</u>	<u>0.5</u>	<u>1.0</u>	<u>5.0</u>	
	3	37	1200	190	1100	1000	640
	6	4.3	67	110	150	150	110
20	C1	4.2*	406*	619*	493*	557*	557*
	C2	<1.8	140	250	750	750	750
	C3			10.5*	340*	550*	296*
	C4			<6.4	<6.4	1200	1200

*Average of the values obtained in three separate

25 assays.

The results shown in TABLE 3 show that the compounds of Examples 3 and 6 induce biosynthesis of 30 interferon in human cells.

ANTIVIRAL ACTIVITY IN GUINEA PIGS

The test methods described below demonstrate the ability of compounds of the invention to reduce the 35 number and severity of lesions developed by guinea pigs infected with Type II Herpes simplex virus.

- 17 -

Female Hartley guinea pigs weighing 200 to 250 g are anesthetized with methoxyflurane (available under the tradename Metafane from Pitman-Moore, Inc., Washington Crossing, NJ), after which the vaginal area 5 is swabbed with a dry cotton swab. The guinea pigs are then infected intravaginally with a cotton swab saturated with Herpes simplex virus Type II strain 333 (1 X 10⁵ plaque forming units/mL). Guinea pigs are assigned to groups of 7 animals; one group for each 10 treatment and one to serve as a control (vehicle treated). The compounds of the invention are formulated in water containing 5% Tween 80 (a polyoxyethylene sorbitan monooleate available from Aldrich Chemical Company, Inc., Milwaukee, WI). The guinea pigs are 15 treated orally once daily for four consecutive days starting 24 hours after infection.

Antiviral activity is evaluated by comparing lesion development in compound treated versus vehicle treated guinea pigs. External lesions are scored 4, 7, 20 8 and 9 days after infection using the following scale: 0 - no lesion, 1 - redness and swelling, 2 - a few small vesicles, 3 - several large vesicles, 4 - large ulcers with necrosis and 5 - paralysis. The maximum lesion score of each guinea pig is used to calculate 25 the percentage lesion inhibition. The percentage lesion inhibition is calculated as follows:

$$30 \quad 100 - \frac{\text{Sum of maximum lesions scores of treat group}}{\text{Sum of maximum lesion scores of vehicle group}} \times 100$$

Results are shown in Table 4.

- 18 -

TABLE 4

ANTIVIRAL ACTIVITY IN GUINEA PIGS

	Compound of Example	Dose mg/Kg	% Lesion Inhibition
5	3	0.3	56
	3	0.1	13
10	3	0.03	37
	6	1	100
	6	0.5	100
	6	0.3	93
	6	0.1	0
	C1	0.5	100
15	C1	0.1	50
	C2	2	100
	C3	3	96
	C3	2	56*
	C3	1	14
20	C4	1	100

*Average value from three separate assays


25 The results in TABLE 4 show that the compounds of Examples 3 and 6 reduce the number of lesions developed by guinea pigs infected with Type II Herpes simplex virus.

- 19 -

CLAIMS:

1. A compound of the formula:

5



10

wherein R₁ is 2-methylpropyl or 2-hydroxy-2-methylpropyl, or a pharmaceutically acceptable acid addition salt thereof.

15

2. An antiviral pharmaceutical composition comprising a compound according to Claim 1 and a pharmaceutically acceptable vehicle, the compound being present in an amount effective to inhibit and/or 20 prevent the progress of a viral infection.

25

3. A method of treating a mammal infected with a virus, comprising administering to the mammal a compound according to Claim 1 in an amount effective to inhibit and/or prevent the infection.

4. A method according to Claim 3, wherein the virus is Type II Herpes simplex.

30

5. A method of inducing interferon biosynthesis in a mammal, which method comprises administering to the mammal a compound according to Claim 1 in an amount sufficient to induce interferon biosynthesis.

35


6. A method of inducing tumor necrosis factor biosynthesis in a mammal, which method comprises administering to the mammal a compound according to

- 20 -

Claim 1 in an amount sufficient to induce tumor necrosis factor biosynthesis.

7. A compound of the formula:

5




10

wherein R₁ is 2-methylpropyl or 2-hydroxy-2-methylpropyl.

15

8. A compound of the formula:

20



wherein R₁ is 2-methylpropyl or 2-hydroxy-2-methylpropyl.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 92/09018

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C07D471/04; A61K31/44; // (C07D471/04, 235:00, 221:00)

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols
Int.Cl. 5	C07D ; A61K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP,A,0 145 340 (RIKER LABORATORIES) 19 June 1985 cited in the application see claims 1,2,9,12 ----	1,2,7,8
X	EP,A,0 385 630 (RIKER LABORATORIES) 5 September 1990 see claims 5,7 ----	1,7
A	EP,A,0 389 302 (RIKER LABORATORIES) 26 September 1990 cited in the application see claims 1,4 -----	1,2

¹⁰ Special categories of cited documents :¹⁰^{"A"} document defining the general state of the art which is not considered to be of particular relevance^{"E"} earlier document but published on or after the international filing date^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)^{"O"} document referring to an oral disclosure, use, exhibition or other means^{"P"} document published prior to the international filing date but later than the priority date claimed^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention^{"X"} document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step^{"Y"} document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.^{"&"} document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

25 JANUARY 1993

Date of Mailing of this International Search Report

01.03.93

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

VOYIAZOGLOU D.

INTERNATIONAL SEARCH REPORT

I. national application No.

PCT/US 92/09018

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

"Remark: Although claims 3 - 6 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition."

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

 The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

US 9209018
SA 66075

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

25/01/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0145340	19-06-85	AU-A-	2991189	15-06-89
		AU-B-	581190	16-02-89
		AU-A-	3540284	23-05-85
		CA-A-	1271477	10-07-90
		EP-A, B	0310950	12-04-89
		JP-A-	60123488	02-07-85
		US-A-	4698348	06-10-87
		US-A-	4689338	25-08-87
<hr/>				
EP-A-0385630	05-09-90	AU-B-	630921	12-11-92
		AU-A-	5005490	30-08-90
		CA-A-	2010430	27-08-90
		JP-A-	3027380	05-02-91
<hr/>				
EP-A-0389302	26-09-90	US-A-	4929624	29-05-90
		AU-A-	5142690	27-09-90
		CA-A-	2012226	23-09-90
		JP-A-	3027381	05-02-91
		US-A-	5037986	06-08-91
<hr/>				